	June 30, 2019		December 31, 2018
Raw materials	$	13,480	$	279
Work in process		19,282		14,395
Finished goods		393		2,844
Total inventories	$	33,155	$	17,518

Balance Sheet Classification
Inventories	$	1,547	$	7,873
Inventories, noncurrent portion		31,608		9,645
Total inventories	$	33,155	$	17,518

We began capitalizing inventory for costs associated with Andexxa Gen 1 and Gen 2 supply upon FDA approval on May 3, 2018 and December 31, 2018, respectively. As of June 30, 2019 and December 31, 2018, long-term inventories of $31.6 million and $9.6 million, respectively, are classified as inventories, noncurrent portion, as these inventories are not expected to be sold within the next twelve months, and the amount is deemed recoverable.

As of June 30, 2019 and December 31, 2018, we have made prepayments to manufacturers for the purchase of inventories. These are classified as short and long-term assets based on when the inventories are expected to be utilized in the manufacturing process and/or sold within the next twelve months. As of June 30, 2019 and December 31, 2018, long-term prepaid manufacturing of $7.8 million and $10.9 million, respectively, are classified as prepaid and other long-term assets as these inventories are not expected to be utilized in the manufacturing process and/or sold within the next twelve months.

We recorded an excess and obsolescence inventory charge to cost of sales of $3.8 million during the six months ended June 30, 2019. In developing the estimate for inventory reserve, we used estimates of demand compared to shelf life. If it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required.

	June 30, 2019		December 31, 2018
Manufacturing related	$	7,280	$	5,465
Compensation and employee benefits		14,217		10,794
Current portion of lease liability		3,004		—
Others		8,741		6,051
Total accrued and other liabilities	$	33,242	$	22,310